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Abstract
Purpose: To examine the effect of lymph node dissection on the outcomes of pa-
tients who underwent salvage radical prostatectomy (SRP).
Material and Methods: We retrospectively reviewed data from radiation‐recurrent
patients with prostate cancer (PCa) who underwent SRP from 2000–2016. None of
the patients had clinical lymph node involvement before SRP. The effect of the
number of removed lymph nodes (RLNs) and the number of positive lymph nodes
(PLNs) on biochemical recurrence (BCR)‐free survival, metastases free survival, and
overall survival (OS) was tested in multivariable Cox regression analyses.
Results: About 334 patients underwent SRP and pelvic lymph node dissection
(PLND). Lymph node involvement was associated with increased risk of BCR
(p < .001), metastasis (p < .001), and overall mortality (p = .006). In a multivariable
Cox regression analysis, an increased number of RLNs significantly lowered the risk
of BCR (hazard ratio [HR] 0.96, p = .01). In patients with positive lymph nodes, a
higher number of RLNs and a lower number of PLNs were associated with improved
freedom from BCR (HR 0.89, p = .001 and HR 1.34, p = .008, respectively). At a
median follow‐up of 23.9 months (interquartile range, 4.7–37.7), neither the number
of RLNs nor the number of PLNs were associated with OS (p = .69 and p = .34,
respectively).
Conclusion: Pathologic lymph node involvement increased the risk of BCR, metas-
tasis and overall mortality in radiation‐recurrent PCa patients undergoing SRP. The
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risk of BCR decreased steadily with a higher number of RLNs during SRP. Further
research is needed to support this conclusion and develop a precise therapeutic
adjuvant strategy based on the number of RLNs and PLNs.
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1 | INTRODUCTION
Prostate cancer (PCa) is estimated to be the most commonly di-
agnosed cancer in men and the second leading cause of cancer‐
related deaths in the United States in 2020.1 It is estimated that
approximately one‐third of patients with clinically nonmetastatic
PCa undergo primary radiation therapy, with 30%–60% of patients
eventually experiencing biochemical recurrence (BCR).2–7 If not
treated, approximately half of these patients will experience distant
metastasis.5,7,8 Salvage radical prostatectomy (SRP) can offer dur-
able disease control and the possibility of a cure for nonmetastatic
radiation‐recurrent patients with PCa.
Several studies have reported 10‐year cancer‐specific survival
of up to 70%–83% for patients undergoing SRP.9–11 However,
despite the potential survival benefit, SRP is still underutilized in
clinical practice. According to the Cancer of the Prostate Strategic
Urologic Research Endeavor (CaPSURE) database, only 2% of pa-
tients with radiation‐recurrent prostate cancer undergo SRP.12
This is likely due to the fear of the associated high rate of com-
plications that were described in earlier reports.13,14 However,
modern series have demonstrated a significantly reduced SRP
morbidity, mainly due to improved radiation therapy and surgical
techniques.9,10
The role of pelvic lymph node dissection (PLND) in SRP is
poorly investigated and its benefits are still inconclusive. There-
fore, in this study, we sought to evaluate the impact of the number
of removed lymph nodes (RLNs) and the number of positive lymph
nodes (PLNs) in a large multicentric cohort of patients with
radiation‐recurrent clinically nonmetastatic PCa treated with SRP
and PLND.
2 | MATERIAL AND METHODS
2.1 | Patient population and treatment
Six participating centers provided information on men treated with
SRP. We retrospectively reviewed 334 patients with radiation‐
recurrent PCa treated with SRP between 2007 and 2016. Clinical
staging was performed using conventional imaging and none of the
patients had clinical lymph node involvement before SRP. All patients
underwent SRP with concomitant PLND. The radiotherapy mod-
alities included brachytherapy, external beam radiation therapy
(EBRT), or between distinct radiotherapy techniques (EBRT and
brachytherapy, EBRT and intensity‐modulated radiation therapy, or
EBRT and three‐dimensional conformal radiation therapy). BCR after
radiotherapy was defined as prostatic specific antigen (PSA) increase
of ≥ 2 ng/ml greater than the nadir, according to the Radiation
Therapy Oncology Group‐American Society for Radiation Oncology‐
Phoenix criteria.15 A pre‐SRP biopsy was performed in all patients to
confirm the diagnosis of locally recurrent PCa. All patients under-
went open surgical SRP with PLND.
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All prostate specimens were staged according to the 2007
American Joint Committee on Cancer TNM staging system by ex-
perienced genitourinary pathologists.16,17
2.2 | Follow‐up
The postoperative follow‐up was performed according to institu-
tional protocols. In general, the patients were followed every three
months within the first two years and every six months thereafter.
BCR after SRP was defined as a total PSA value of ≥ 0.2 ng/ml. No
patients received adjuvant androgen deprivation therapy before the
diagnosis of BCR. Distant metastases were identified using radiologic
imaging.18 All study time intervals and follow‐up durations were
calculated from the date of surgery to the analyzed event.19
2.3 | Statistical analysis
Univariable and multivariable Cox regression analyses were per-
formed to determine the association of the number of RLNs and the
number of PLNs with BCR free survival, metastases‐free survival
(MFS), and overall survival (OS). The association between the num-
ber of RLNs and the probability of lymph node involvement was
assessed by logistic regression analysis. Results were considered
significant if the two‐sided p value was less than .05. Data analyses
were performed using STATA 16 (Stata Corp.).
3 | RESULTS
3.1 | Clinical and pathologic characteristics
The clinical and pathologic features of the 334 men with radiation‐
recurrent PCa treated with SRP with PLND are summarized in Table 1.
The median patients' age at SRP was 68 years (interquartile range [IQR]:
63–72). The median pre‐SRP PSA was 3.55 ng/ml (IQR: 2.2–6.2) and
Gleason Score (GS)≥8 was found in 119 (35.8%) patients on pre‐SRP
biopsy. Pathologic lymph node involvement was found in 19.8% of the
patients. The median number of removed lymph nodes was 13 (IQR:
10–17). The median follow‐up duration was 23.9 months (IQR: 4.7–34.7).
In a multivariable logistic regression analysis, a higher number of
RLNs was associated with an increased probability of finding positive
lymph nodes (odds ratio [OR] 1.11, 95% confidence interval [CI]:
1.05–1.17, p < .001) (Figure 1).
3.2 | Association with biochemical
recurrence (BCR)
During follow‐up, 137 patients (41.1%) developed BCR. On multi-
variabke cox regression analysis, lymph node involvement was sig-
nificantly associated with a higher risk of BCR (HR 1.75, 95% CI:
TABLE 1 Clinicopathologic characteristics of patients with
radiation recurrent prostate cancer undergoing salvage radical
prostatectomy
Patients number 344
Age at SRP, year, median (IQR) 68 (63–72)
Total PSA before radiotherapy, median (IQR) 6.2 (4.1–10)




Total PSA before SRP, median (IQR) 3.55 (2.2–6.2)




Pathological Gleason score, n (%)
G6 28 (8.4)
G7 161 (48.5)
G ≥ 8 143 (43.1)
Positive surgical margins, n (%) 87 (26.1)
Extracapsular extension, n (%) 48 (14.4)
Seminal vesicle invasion, n (%) 113 (33.8)
Lymph node metastasis, n (%) 66 (19.8)
Number of removed lymph nodes, median (IQR) 13 (10–17)
Number of positive lymph nodes, median (IQR) 1 (1–2)
Abbreviations: IQR, interquartile range; PSA, prostatic specific antigen;
SRP, salvage radical prostatectomy.
F IGURE 1 The predicted probability of detecting positive lymph
nodes by the number of removed nodes
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1.12–2.74, p = .014). On multivariable Cox regression analysis, the
risk of BCR decreased with increased number of RLNs after adjust-
ments for the effect of established pathologic confounders (HR 0.96,
95% CI: 0.93–0.99, p = .01) (Table 2).
In a subgroup of 66 patients with positive lymph node involve-
ment (Table 3), multivariable Cox regression analysis revealed that a
higher number of RLNs and a lower number of PLNs were both
associated with improved freedom from BCR (HR 0.89, 95% CI:
0.83–0.96, p = .001 and HR 1.34, 95% CI: 1.08–1.66, p = .008, re-
spectively). Patients with at least two positive lymph nodes had a
significantly higher risk of developing BCR (log‐rank p < .001)
(Figure 2A).
TABLE 2 Multivariable Cox regression analysis evaluating the impact of the number of removed lymph nodes during salvage radical
prostatectomy on biochemical recurrence, metastasis, and overall mortality
Biochemical recurrence Metastasis Overall mortality
HR 95% CI p HR 95% CI p HR 95% CI p
Seminal vesicle invasion 1.81 1.21–2.7 .004 1.76 0.91–3.41 .09 1.58 0.71–3.49 .26
Extracapsular extension 2.24 1.35–3.74 .002 2.21 0.92–5.3 .074 0.79 0.17–3.63 .76
Positive surgical margins 1.27 0.88–1.85 .19 1.63 0.92–2.87 .09 1.28 0.59–2.77 .52
Pathological Gleason score
7 1.43 0.61–3.39 .41 1.79 0.22–14.19 .58 1.02 0.21–4.88 .98
≥8 3.02 1.27–7.18 .012 9.69 1.27–73.93 .029 4.07 0.86–19.21 .08
Number of removed lymph nodes (cont.) 0.96 0.93–0.99 .01 1.01 0.96–1.07 .58 0.93 0.86–1.004 .064
Abbreviations: CI, confidence interval; HR, hazard ratio.
TABLE 3 Multivariable Cox regression analysis evaluating the impact of the number of removed lymph nodes during salvage radical
prostatectomy on biochemical recurrence and metastasis in subgroup of patients with pathologic lymph node involvement
Biochemical recurrence Metastasis
HR 95% CI p HR 95% CI p
Seminal vesicle invasion 1.52 0.59–3.92 0.39 0.69 0.19‐2.46 0.57
Extracapsular extension 1.99 0.64–6.22 0.24 0.99 0.19‐5.14 0.99
Positive surgical margins 0.45 0.19–1.06 0.07 1.56 0.56‐4.31 0.39
Pathological Gleason score 0.88 0.60–1.29 0.52 1.93 1.11‐3.33 0.019
Number of removed lymph nodes (cont.) 0.89 0.84–0.96 0.001 0.98 0.91‐1.06 0.67
Number of positive nodes (cont.) 1.37 1.11–1.69 0.003 1.31 1.02‐1.67 0.033
Abbreviations: CI, confidence interval; HR, hazard ratio.
F IGURE 2 Kaplan–Meier curves showing the association between the number of positive lymph nodes and the risk of: (A) BCR, (B)
metastasis in patients undergoing salvage radical prostatectomy for radiation recurrent prostate cancer. BCR, biochemical recurrence
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3.3 | Association with metastasis
During follow‐up, 53 patients (15.9%) developed metastasis. Lymph
node involvement was associated with an increased risk of devel-
oping metastasis (HR 3.93, 95% CI: 2.26–6.85, p < .001). On a mul-
tivariable Cox regression analysis, the number of RLNs did not
influence the risk of developing metastasis after adjustments for the
effects of established pathologic confounders (HR 1.01, 95% CI:
0.96–1.07, p = .58) (Table 2).
In a subgroup of 66 patients with positive lymph node involve-
ment, a multivariable Cox regression analysis revealed no statisti-
cally significant association between the number of RLNs and the
risk of metastasis (HR 0.98, 95% CI: 0.91–1.06, p = .67). A higher
number of PLNs showed a statistically significant increase risk of
metastasis (HR 1.31, 95% CI: 1.02–1.67, p = .033) (Table 3). Patients
with more than or equal to two positive lymph nodes had a sig-
nificantly higher risk of experiencing metastasis (log‐rank p = .004)
(Figure 2B).
3.4 | Association with overall survival (OS)
During follow‐up, 32 patients (9.6%) died. Lymph node involvement
was associated with an increased risk of overall mortality (HR 2.88,
95% CI: 1.36–6.13, p = .006). On a multivariable Cox regression
analysis, the number of RLNs was not associated with OS (HR 0.93,
95% CI: 0.86–1.004, p = .064)) (Table 2).
In a subgroup of 66 patients with positive lymph node involve-
ment, a multivariable Cox regression analysis showed no statistically
significant association between the number of RLNs and the number
of PLNs with OS (HR 0.94, 95% CI:0.82–1.06, p = .31 and HR 1.08,
95% CI: 0.61–1.91, p = .78, respectively).
4 | DISCUSSION
In this large multicentric study, we tested the impact of the number
of RLNs and the number of PLNs in patients with radiation‐recurrent
clinically nonmetastatic PCa treated with SRP and PLND.
Patients with pathologic lymph node involvement were at sig-
nificantly increased risk of BCR, metastasis, and overall mortality.
Although non of the patients in our study had clinical lymph node
involvement, 19.8% of patients were found to have pathologic lymph
node involvement, which is comparable to previous SRP reports. For
example, Heidenreich et al.10 reported a 20% rate of positive lymph
nodes in patients undergoing SRP with PLND, highlighting the im-
portant staging role of PLND in these patients.
One of the key findings of our study was that a higher number of
RLNs leads to lower risk of BCR. Several studies have investigated
the prognostic effect of the number of RLNs in primary radical
prostatectomy yielding contrasting results.20–22 However, due to the
different natural history of radiation‐recurrent PCa undergoing SRP,
data from primary radical prostatectomy cannot be extrapolated to
radiation‐recurrent PCa patients planned for SRP.16,17,23 In a report
from the Surveillance, Epidemiology, End Results registry (SEER)
evaluating 364 patients who underwent SRP between 1988 and
2010, Pokala et al.24 did not find a significant association between
the number of RLNs and cancer‐specific survival (HR 0.5, 95% CI:
0.2–1.4, p = .2).24 However, a more recent analysis of the SEER da-
tabase which included patients who were treated between 2004 and
2016, Wenzel et al.25 did demonstrate a significantly lower cancer‐
specific mortality with a higher number of removed nodes (HR: 0.61,
CI: 0.40–0.91; p = .02). Both studies did not report on the association
with BCR. In our study of 334 SRPs performed at tertiary referral
centers, we demonstrated that the number of RLNs was associated
with the risk of BCR. Although the clinical relevance of BCR and its
impact on survival have been debated in general, in this cohort of
salvage patients, BCR is certainly a more reliable surrogate endpoint
for OS.26 Moreover, it is possible that the adverse events associated
with androgen depreviation therapy (ADT), which is used in patients
who develop BCR, can contribute to the worse OS.27 In general, we
believe that further studies with longer follow‐up are needed to
determine the prognostic value of BCR after SRP.
The extent of lymph node dissection is an important factor in the
likelihood of finding positive lymph nodes. In our study, there was a
significantly higher probability of detecting positive lymph nodes
with an increased number of RLNs. The relationship between in-
creased node yield and the probability of finding lymph node in-
volvement has not been previously evaluated in SRP patients.
However, this association was demonstrated in patients undergoing
primary RP. Briganti et al.28 evaluated 858 patients treated with
primary RP and extended PLND. In their study, they demonstrated a
90% ability to detect positive nodes in patients with more than or
equal to 28 RLNs as compared to less than 10% in patients in pa-
tients with less than or equal to 10 RLNs.28 In the case of primary
radical prostatectomy, patients with lymph node involvement would
be informed about the risks, benefits, and alternatives to adjuvant
therapy. For SRP, there is currently no optimal management, with
irradiation of the lymph nodes area if not done previously or an-
drogen deprivation therapy being possible options. Nevertheless, our
results indicate that patients with radiation‐recurrent PCa, treated
with SRP should undergo extensive PLND, which provides a better
staging of the disease and may even result in better short‐term on-
cologic outcomes. Despite concerns of the associated high rate of
complications that were described in old reports,13,14 modern series
have demonstrated a reduced SRP morbidity, mainly due to im-
proved radiation therapy and surgical techniques.9,10
Our study has limitations, including its retrospective study design.
Furthermore, no central pathological review was performed. We were
not able to report on other clinically meaningful events such as cancer‐
specific survival because of the limited follow‐up duration.29,30 Moreover,
all patients in our series were staged using conventional imaging, due to
the limited availability of prostate‐specific membrane antigen positron
emission tomography/computed tomography (PSMA PET/CT) at the time
of study enrollment.31–33 Indeed, several studies have demonstrated the
superiority of PSMA PET/CT over conventional imaging in staging
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patients with radiation recurrent PCa.34,35 Despite these limitations, we
were able to present the first study to comprehensively analyze the role
of lymph node yield and the number of positive lymph nodes in patients
with radiation recurrent PCa treated with SRP.
5 | CONCLUSION
Lymph node involvement increased the risk of BCR, metastasis, and
overall mortality in radiation‐recurrent PCa patients undergoing SRP. A
higher number of removed lymph nodes improved staging leading to a
higher probability of detecting lymph node metastasis. Furthermore, an
increased number of removed nodes during SRP reduced the risk of BCR,
hinting at a possible therapeutic benefit. Moreover, the poor prognosis of
patients with more than two positive lymph nodes highlights the need for
further adjuvant treatments and closer follow‐up of these patients. We
believe the findings in our study should support performing extended
PLND in patients undergoing SRP. Further research with standardized
lymph node templates is still needed to support this conclusion and de-
velop a precise therapeutic adjuvant strategy based on the number of
RLNs and the number of PLNs.
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